27 results
Thumbnail

D1.428 - Fungal Microbiome Diversity in Urban Forest Decreases Asthma and Allergic Inflammation

Thumbnail

D1.431 - Associations of the composition of intestinal microbiota with the initial manifestations of IgE-mediated food allergy in children 6-12 months old

Thumbnail

D1.433 - The effect of preventive administration of probiotic strain E. coli 083:H24:K31 on selected immune characteristics of eight-year-old children

Thumbnail

D2.230 - Cross-Reactivity of Cephalosporins in Patients with IgE-Mediated Allergy to Penicillins: A Systematic Review

Thumbnail

D2.231 - The experiences of ferric carboxymaltose desensitization and provocation

Thumbnail

D2.232 - SDRIFE related to generalized corticosteroids’ hypersensitivity: A case report

Thumbnail

D2.233 - Negative predictive value of skin tests with local anaesthetics

Thumbnail

D2.235 - Is an allergy skin test with local anaesthetics necessary? Real life data with 124 patients

Thumbnail

D2.236 - Drug-induced angioedema by racecadotril in a patient treated with angiotensin-converting enzyme inhibitors

Thumbnail

D2.237 - Corticosteroid allergy, hypertryptasemia and renal transplant

Thumbnail

D2.238 - Successful Prevention of Subsequent L-Asparaginase Hypersensitivity in Children through Premedication: A Single-Center Experience

Thumbnail

D2.239 - The First Successful Desensitization in Abemaciclib Hypersensitivity: A Case Report

Thumbnail

D2.242 - Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a Romanian University Hospital

Thumbnail

D2.243 - From Risk to Solution: Effective Desensitization in a Confirmed Delayed Hypersensitivity Reaction to Albendazole

Thumbnail

D2.245 - Long-Term Outcomes of Beta-Lactam Allergy De-Labelling: A Retrospective 10 year Analysis of Patient Confidence and Antibiotic Tolerance

Thumbnail

D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria

Thumbnail

D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria

Thumbnail

D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117

Thumbnail

D2.354 - Questionnaire survey of new treatments for atopic dermatitis

Thumbnail

D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria